title: Orexin-B-saporin lesions in the lateral hypothalamus enhance photic masking of rapid eye movement sleep in the albino rat.
abstract: The 24-h distribution of rapid eye movement (REM) sleep is known to be deeply reshaped among albino rats with neurotoxic lesions in the lateral hypothalamus (LH) or among rodent models of human narcolepsy-cataplexy, with selective damage of orexinergic neurones. We explored the hypothesis that this phenomenon is explained by an enhancement of REM sleep photic masking, as a consequence of damage in the LH. Orexin-B-saporin neurotoxic lesions were induced in the LH of male Sprague-Dawley rats. LH-lesioned and control rats were sleep-recorded successively under 12:12 light/dark (LD) and skeleton photoperiod. Compared to controls, lesioned rats exhibited 50% less and 82% more REM sleep during rest and active phases, respectively, under the 12:12 LD schedule. After transference to a skeleton photoperiod, lesioned rats exhibited an 88% increase in REM sleep during the rest phase, recovering the characteristic rest phase preference of REM sleep observed among control rats. The increase in rest phase REM sleep during the skeleton photoperiod was correlated positively with the magnitude of the LH lesion. Our results suggest that changes in the temporal organization of sleep-wake states observed among rats with neurotoxic lesions in the lateral hypothalamus and rodent models of narcolepsy-cataplexy may be explained by the enhancement of photic masking.
authors.affiliation: Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile. aocampo@med.uchile.cl
authors.forename: Adrián
authors.initials: A
authors.lastname: Ocampo-Garcés
authors.forename: Francisco
authors.initials: F
authors.lastname: Ibáñez
authors.forename: Guetón
authors.initials: G
authors.lastname: Perdomo
authors.forename: Fernando
authors.initials: F
authors.lastname: Torrealba
mesh_terms: D000818:Animals; D002452:Cell Count; D004569:Electroencephalography; D007031:Hypothalamus / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D047908:Intracellular Signaling Peptides and Proteins / Q000494:pharmacology*; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D009479:Neuropeptides / Q000494:pharmacology*; D000068797:Orexins; D010775:Photic Stimulation; D051381:Rats; D017207:Rats, Sprague-Dawley; D054789:Ribosome Inactivating Proteins, Type 1 / Q000494:pharmacology*; D000076985:Saporins; D020178:Sleep Disorders, Circadian Rhythm / Q000473:pathology / Q000503:physiopathology; D012895:Sleep, REM / Q000502:physiology*; D014851:Wakefulness / Q000502:physiology
chemical_list: C000596229:HCRT protein, human; D047908:Intracellular Signaling Peptides and Proteins; D009479:Neuropeptides; D000068797:Orexins; D054789:Ribosome Inactivating Proteins, Type 1; D000076985:Saporins